• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BSGM

    BioSig Technologies Inc.

    Subscribe to $BSGM
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

    IPO Year:

    Exchange: NASDAQ

    Website: biosig.com

    Recent Analyst Ratings for BioSig Technologies Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    BioSig Technologies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on BioSig Technologies with a new price target

    The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

    2/8/21 7:32:50 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

    LOS ANGELES & VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which recently merged with Streamex Exchange Corporation ("Streamex") (together, "BSGM" or the "Company"), announced today that it will change its name to Streamex Corp., effective at 12:01 am Eastern Time on Friday, September 12, 2025. In connection with the name change, the Company will change its trading symbol to "STEX." The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on September 12, 2025. As of September 12, 2025, all Company stock trading, filings, and market related information

    9/10/25 11:54:24 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Monetary Metals Enters into Exclusive Partnership with Streamex (Nasdaq: BSGM) to Create Tokenized Yield-Bearing Gold Products

    Monetary Metals has signed an agreement with Streamex to provide yield on physical gold bullion with upwards of $1 billion USD in near term lease capacity SCOTTSDALE, Ariz. and LOS ANGELES, Sept. 9, 2025 /PRNewswire/ -- Monetary Metals, the pioneer in gold-and-silver-denominated fixed income products, has partnered with Streamex Exchange Corporation ("Streamex"), which recently merged with BioSig Technologies Inc. (NASDAQ:BSGM). Through this collaboration, Monetary Metals will gain exclusive rights to put Streamex's tokenized gold to work earning yield. The partnership adds an important new channel to bring gold to the Monetary Metals Gold Yield Marketplace® with a well-capitalized Nasdaq l

    9/9/25 8:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

    Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings Key Partnership Highlights Streamex secures exclusive tokenization rights for yield-bearing gold products through Monetary MetalsInvestors gain access to an estimated four percent (4%) annual yield through tokenized bullion assets and gold treasuryStrategic structure includes revenue share tied to gold leasing volumes on Monetary Metals' platform LOS ANGELES and SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioSig Technologi

    9/8/25 10:10:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

    LOS ANGELES and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), today provided an update regarding the status of the merger and related proxy materials. The merger transaction closed on May 28, 2025, under the previously executed Share Purchase Agreement. As part of this transaction, 19.99% of BioSig shares are already issuable to Streamex shareholders, with the remaining issuances pending Nasdaq approval. In connection with the Company's Schedule 14A filings, the Board of Directors has determined that, due to pending Nasdaq approval,

    9/2/25 10:59:13 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex (BSGM) to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

    LOS ANGELES, CA & VANCOUVER, BC , Aug. 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), a gold tokenization infrastructure company building the foundation for on-chain gold markets, today announced that it will participate in the 5th annual Needham Virtual Crypto 1x1 Conference on September 4th, 2025. BioSig and Streamex CEO, Henry McPhie and CIO, Mitch Williams will host one on one meetings with institutional investors at the conference. About Streamex Streamex is an RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market

    8/28/25 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

    Los Angeles, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), a gold tokenization infrastructure company, today announced the closing of its previously announced underwritten public offering, including a group of technology and mining thought leaders. The offering consisted of 3,852,149 shares of common stock at a public offering price of $3.90 per share with no pre-funded warrants. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses were approximately $15,023,381. The Company inte

    8/15/25 4:50:14 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

    Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offerin

    8/13/25 11:10:13 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Announces Proposed Public Offering

    Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company") which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, fo

    8/13/25 5:16:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BSGM Engages CXG to Acquire FINRA/SEC-Registered Broker-Dealer to Expand Publicly Traded RWA Tokenization Operations

    Will Position Streamex as one of the first NASDAQ Listed SEC and FINRA Compliant Issuers of RWA Tokens in the U.S. BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which recently merged with Streamex Exchange Corporation ("Streamex") (together, "BSGM" or the "Company"), is excited to announce a critical step toward becoming one of the first fully regulated Real-World Asset ("RWA") tokenization companies trading on a major United States exchange: Streamex has engaged Compliance Exchange Group (CXG) to lead and manage the acquisition of a specific FINRA and SEC registered broker-dealer with licensed operations. This press release features multimedia. View the full release here: https://

    7/14/25 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Williams Mitchell Young claimed ownership of 1,000,000 units of Restricted Common Stock (SEC Form 3)

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:31:07 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mcphie Karl Henry Michael

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:29:42 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Lekstrom Morgan Lee

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:27:01 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim CFO Groenewald Ferdinand was granted 175,000 shares, increasing direct ownership by 292% to 235,000 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/2/25 5:30:31 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Amato Anthony N. was granted 900,000 shares, increasing direct ownership by 42% to 3,031,547 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/2/25 5:30:32 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim CFO Groenewald Ferdinand was granted 35,000 shares, increasing direct ownership by 140% to 60,000 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    4/29/25 6:28:56 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Amato Anthony N. was granted 23,345 shares, increasing direct ownership by 1% to 2,131,547 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    4/29/25 6:28:54 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Abelman Steven Eric was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    4/29/25 6:28:47 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Baer Christopher Allen was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    4/29/25 6:28:49 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Browne Donald was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

    4 - BioSig Technologies, Inc. (0001530766) (Issuer)

    4/29/25 6:28:50 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. SEC Filings

    View All

    BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BioSig Technologies, Inc. (0001530766) (Filer)

    9/8/25 3:59:06 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - BioSig Technologies, Inc. (0001530766) (Filer)

    9/5/25 5:26:42 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by BioSig Technologies Inc.

    DEFA14A - BioSig Technologies, Inc. (0001530766) (Filer)

    9/3/25 9:06:24 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFR14A filed by BioSig Technologies Inc.

    DEFR14A - BioSig Technologies, Inc. (0001530766) (Filer)

    9/3/25 6:05:06 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFR14A filed by BioSig Technologies Inc.

    DEFR14A - BioSig Technologies, Inc. (0001530766) (Filer)

    9/2/25 4:38:38 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 5:15:46 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by BioSig Technologies Inc.

    10-Q - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 4:53:03 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFR14A filed by BioSig Technologies Inc.

    DEFR14A - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 4:15:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by BioSig Technologies Inc.

    424B5 - BioSig Technologies, Inc. (0001530766) (Filer)

    8/14/25 4:00:47 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by BioSig Technologies Inc.

    424B5 - BioSig Technologies, Inc. (0001530766) (Filer)

    8/13/25 5:15:18 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Financials

    Live finance-specific insights

    View All

    BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

    Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

    9/22/22 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig to Host Conference Call on December 21, 2021

    Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

    12/13/21 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by BioSig Technologies Inc.

    SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

    2/14/24 3:31:45 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    7/12/21 8:29:21 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed

    SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

    2/2/21 3:13:40 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Leadership Updates

    Live Leadership Updates

    View All

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

    Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

    6/9/25 10:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

    Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

    6/4/25 8:25:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CORRECTION: Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

    Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies' leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company. Mr, Williams, brings over 20 years of

    5/28/25 6:45:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer

    Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "combined company"), which today acquired Streamex Exchange Corporation ("Streamex") as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company's leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex, will be appointed Chief Investment Officer of the combined company. Mr. Willi

    5/28/25 1:46:57 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq

    Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced successful completion of the previously disclosed share exchange transaction and executive leadership changes, forming a company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. Key Highlights of the Transaction: Streamex Exchange Corporation, a British Columbia corporation, will become a wholly owned subsidiary of BioSig through an exchange of outstanding shares of Streamex for new shares of BioSig common

    5/28/25 1:07:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain.

    Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company, today announced it has signed a definitive share exchange agreement with Streamex Exchange Corporation ("Streamex"), a privately held company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. The signing of the definitive agreement represents a major milestone for both Streamex and BioSig, propelling the business combination forward, and fast-tracking the growth of Streamex's tokenization business. During this transaction, Streamex has made significant progress with some ve

    5/23/25 7:56:43 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

    Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

    5/5/25 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

    Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director

    6/10/24 9:45:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

    Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer ("CEO"), effective immediately.  Additionally, Mr. Amato will serve on the Company's Board of Directors, which is currently being assembled.  Recall, that on April 4, 2024, the Company announced the engagement of Consulting firm, Bridge Associates International Pharmaceutical Consulting ("BAIPC"), led by Mr. Amato.  This corporate action was the natural progressi

    4/30/24 2:03:14 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care